BPC-157 and Compounding Pharmacies: FDA Rules Explained

The BPC-157 compounding pharmacy question is one of the most contested issues in peptide regulation. While compounding pharmacies have emerged as a principal route for distributing BPC-157, the FDA has yet to grant authorization for BPC-157 as a bulk substance for compounding. This website describes the 503A and 503B systems, the PCAC vote, and the implications of these existing regulations for pharmacies, prescribers and patients.

Can Compounding Pharmacies Make BPC-157?

The Short Answer

As of October 2026, BPC-157 is not on the FDA's 503A bulks list. It does not have a USP/NF monograph. It is not a component of any FDA-approved drug. Under the strict reading of the law, compounding pharmacies cannot legally use BPC-157 as a bulk drug substance. In practice, some compounding pharmacies continue to prepare BPC-157 formulations, operating in a contested legal space between the PCAC's recommendation and the FDA's final decision.

Section 503A, Traditional Compounding

What 503A Allows

Section 503A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353a) provides for exemptions for some compounded drug products from the new drug approval requirements. To be eligible for the exemption, the compounded drug product must be produced by a licensed physician or pharmacist using the following criteria: it must be based on a valid prescription for a particular patient.

Bulk Drug Substance Criteria

In order to comply with the compounding law under 503A, the bulk drug substances used in compounding must fulfill any of the following conditions: it is an ingredient in an FDA approved drug; its production follows the standards of the USP or NF monographs; or it is included in the FDA's list of approved bulk substances (the "503A bulks list"). BPC-157 does not meet any of these requirements.

Section 503B, Outsourcing Facilities

What 503B Allows

According to Section 503B (21 U.S.C. § 353b), a new class of registered outsourcing facilities has been formed which can manufacture large quantities of drugs without the requirement of individual prescriptions. These outsourcing facilities need registration with FDA and must abide by current Good Manufacturing Practice (cGMP) rules and submit to an FDA inspection. The active ingredients used by these facilities should have met the requirements of 503A or should be listed on FDA's 503B bulks list.

BPC-157 Under 503B

BPC-157 is not included amongst those items that are listed in the 503B bulks list. Similar to traditional compounding pharmacies, outsourcing facilities also face legal hurdles when it comes to their use. The FDA has inspected outsourcing facilities and reported the usage of BPC-157 in warning letters that were issued to some of the facilities including Tailor Made Compounding.

The PCAC Vote, July 2026

What the Committee Voted

The FDA's Pharmacy Compounding Advisory Committee met on July 23-24, 2026 to evaluate BPC-157 (free base) and BPC-157 acetate for potential inclusion on the 503A bulks list. The nominated indication was ulcerative colitis. The FDA staff recommended against inclusion, citing insufficient safety and efficacy data. The committee voted 8-6, with 1 abstention, to recommend that BPC-157 be added to the list.

What the Vote Means

The PCAC vote is advisory. The FDA is not required to follow it. The committee's recommendation is one input the FDA considers when making its final determination. The FDA has historically followed PCAC recommendations in most cases, but not always. As of October 2026, the FDA has not announced a timeline for its final decision on BPC-157.

What the Vote Does Not Mean

The vote does not give compounding authority to BPC-157. It does not include BPC-157 in the bulks designation list. It does not affect any FDA enforcement letters or import alerts. Compounding pharmacies that misinterpret the PCAC vote as a legal authority are misunderstanding the regulatory process. The vote is a recommendation.

FDA Warning Letters to Compounders

The Enforcement Record

Four pharmacies or outsourcing facilities have received warning letters from the FDA for using BPC-157 as a bulk drug substance. The institutions that received the letters include PD Labs (July 2019), Tailor Made Compounding (April 2020), Guyer Institute / Advanced Nutriceuticals (November 2021), and Barclay, Luke & Pillai Specialty Pharmacy (September 2023). Each of the letters identified the violation as the use of BPC-157 which is currently not in the bulks list and does not have any USP/NF monographs.

What This Tells Pharmacies

The warning letters establish that the FDA considers compounding with BPC-157 to be a violation of the FD&C Act. Pharmacies that continue to compound BPC-157 do so knowing that the FDA has taken this position. The PCAC vote may change the FDA's position in the future, but it has not changed the enforcement posture as of October 2026.

What Happens If BPC-157 Is Added to the Bulks List

For Compounding Pharmacies

In the event that the FDA adopts BPC-157 to the 503A bulks list, licensed compounding pharmacies would be authorized to compound BPC-157 formulations for specific patients who hold valid prescriptions. Quality standards will still be applied, while state pharmacy boards will continue overseeing pharmacy operations. Compounding pharmacies will have to source BPC-157 from suppliers who satisfy the FDA's expected quality standards.

For Prescribers

Doctors could eventually prescribe BPC-157 without worrying about current regulations. The doctor will still need clinical justification and the treatment is still unapproved for use as a drug. However, compounding will give a lawful way to receive the treatment that is currently lacking.

For Patients

Pharmacy-compounded BPC-157 would be available to patients with better quality controls than what is present in the research chemical market. While pharmacy pricing will likely be higher than what research chemical vendors are charging, it will include effort in terms of pharmacy preparation and processing, along with physician oversight.

For Research Chemical Vendors

Approval of a legal compounding pathway would result in competition for research chemical suppliers. Nevertheless, the research chemical market is expected to persist due to the availability of cheaper options and the absence of prescription requirements. The two channels target different customer segments.